



Title	Biotransformation of flurbiprofen by Cunninghamella species
Authors(s)	Amadio, Jessica, Gordon, Katherine, Murphy, Cormac D.
Publication date	2010-09
Publication information	Amadio, Jessica, Katherine Gordon, and Cormac D. Murphy. "Biotransformation of Flurbiprofen by Cunninghamella Species" 76, no. 18 (September, 2010).
Publisher	American Society for Microbiology
Item record/more information	http://hdl.handle.net/10197/3780
Publisher's version (DOI)	10.1128/AEM.01027-10

Downloaded 2023-03-15T17:09:45Z

The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd_oa)



© Some rights reserved. For more information

1 **Biotransformation of flurbiprofen by *Cunninghamella* species**

2 Jessica Amadio, Katherine Gordon and Cormac D. Murphy*

3

4 School of Biomolecular and Biomedical Science, Centre for Synthesis and Chemical

5 Biology, Ardmore House, University College Dublin, Dublin 4, Ireland

6

7 *Corresponding author Fax: +353 (0)1 716 1183, Telephone: +353 (0)1 716 1311, email:

8 Cormac.d.murphy@ucd.ie

9

10 **Abstract**

11 The biotransformation of the fluorinated anti-inflammatory drug flurbiprofen was
12 investigated in *Cunninghamella* spp. Mono- and di-hydroxylated metabolites were detected
13 using gas chromatography-mass spectrometry and fluorine-19 nuclear magnetic resonance
14 spectroscopy, and the major metabolite 4'-hydroxyflurbiprofen was isolated by preparative
15 HPLC. *C. elegans* DSM 1908 and *C. blakesleeana* DSM 1906 also produced a phase II
16 (conjugated) metabolite, which was identified as the sulfated drug via deconjugation
17 experiments.

18 One of the objectives of the recent European Union legislation governing the testing and
19 evaluation of chemicals, REACH (Regulation, Evaluation, Authorisation and Restriction of
20 Chemicals), is to further reduce the need for animals in the testing process. Some
21 microorganisms, such as the zygomycete fungus *Cunninghamella* and actinomycetes
22 bacteria, have been shown to metabolise xenobiotic compounds in an analogous fashion to
23 mammals (3, 5, 11, 17). It was suggested over three decades ago that microorganisms had
24 potential as models of mammalian metabolism (16), although there are concerns about their
25 predictive value (8). Nevertheless, certain microorganisms can be applied to the generation
26 of useful quantities of drug metabolic intermediates (13), which is more desirable than
27 isolation of these compounds from dosed animals, and avoids the concerns often associated
28 with chemical synthesis, such as the use of toxic reagents, and harsh reaction conditions.

29 Owing to the desirable physicochemical properties of the fluorine atom (small Van
30 der Waals radius, electronegativity, strength of the carbon-fluorine bond) approximately 25
31 % of drugs either currently on the market or in the pipeline are fluorinated (12). One such
32 example is flurbiprofen [(*RS*)-2-(2-fluoro-4-biphenyl) propionic acid], which is a non-
33 steroidal anti-inflammatory drug (NSAID) used in the treatment of inflammation caused by
34 arthritis. In humans it is transformed to the phase I (oxidative) metabolites 4'-
35 hydroxyflurbiprofen, 3', 4'-dihydroxyflurbiprofen and 3'-hydroxy, 4'-methoxyflurbiprofen;
36 glucuronide and sulfate conjugates (phase II metabolites) have also been detected (9, 15). In
37 equine urine additional hydroxylated and methoxylated metabolites were detected (20).
38 Tracy et al. (18) demonstrated that only one cytochrome P450 isoform (2C9) is involved in
39 the oxidation of flurbiprofen, which makes the drug a potentially useful *in vivo* probe for this
40 particular isoform. Despite the prevalence of fluorinated drugs, only a handful of
41 investigations have been undertaken to determine the microbial biotransformation of these
42 compounds (7, 21). Here we describe the biotransformation of flurbiprofen by

43 *Cunninghamella* species and the determination of the metabolites by nuclear magnetic
44 resonance spectroscopy (^1H NMR and ^{19}F NMR), GC-MS and HPLC.

45 Three species of *Cunninghamella* were selected for the biotransformation
46 experiments: *C. elegans* (strains DSM 1908, DSM 8217, DSM 63299), *C. echinulata* DSM
47 1905 and *C. blakesleeana* DSM 1906. The fungi were grown on Sabouraud dextrose agar
48 plates (Sigma) for 5 days at 26 °C before being homogenized in 100 ml of sterile saline
49 solution. The homogenate (10 % v/v) was used to inoculate 50 ml of fresh Sabouraud
50 dextrose broth in 250 ml Erlenmeyer flasks, which were incubated at 28 °C with shaking at
51 150 rpm. Following previously established procedures (2), 5 mg of flurbiprofen (Sigma)
52 dissolved in dimethylformamide (20 μl) was added to the cultures after 72 h, and the
53 incubation continued up to a further 120 h. Control experiments were conducted in either the
54 absence of flurbiprofen or fungus. The cultures (supernatant and cells) were sonicated on ice
55 (Sonicator U200S control, IKA Labortechnik) for 5 minutes at 50 % amplitude, with intervals
56 of 30 seconds after each minute to prevent overheating. The sonicates were centrifuged and
57 the supernatant extracted with 50 ml of ethyl acetate, and the extracts evaporated to dryness.

58 **Analysis of fluorinated metabolites.** *C. elegans* DSM 1908 is well known as a model of
59 mammalian drug metabolism (10, 11) and analysis of the organically-extractable metabolites
60 by ^{19}F NMR spectroscopy using a Varian 400 MHz spectrometer revealed that flurbiprofen
61 was completely degraded to one fluorometabolite over three days (Figure 1). The
62 concentration of the metabolite was estimated at by using an internal standard (4-
63 fluorobiphenyl) in ^{19}F NMR analyses, and equated to 2 mg in the culture supernatant. No
64 fluorinated products were detected in uninoculated control flasks.

65 The fluorometabolite was isolated by preparative reversed phase HPLC using a
66 Varian Prostar HPLC system equipped with a Zorbax SB-C18 9.4 mm x 25 cm column
67 (Agilent Technologies). Compounds were eluted with a gradient of acetonitrile/water (20-60

68 % acetonitrile) over 30 minutes at a flow rate of 3.5 ml/min. The main metabolite, which
69 eluted at 19 minutes, was isolated and analysed by ^1H and ^{19}F NMR spectroscopy, and mass
70 spectrometry. The spectrum obtained with ^1H NMR analysis showed resonances at 1.56 ppm
71 (CH_3 , d), 3.78 ppm (CH, q), 6.9 ppm ($\text{C}_{3'}$ and $\text{C}_{5'}$ -H, ddd), 7.14 ppm (C_2 -H, ddd), 7.16 ppm
72 (C_6 -H, ddd), 7.37 ppm (C_5 -H, ddd) 7.43 ppm (C_2' and C_6' -H, ddd). There was no resonance
73 for C_4 -H indicating that the hydroxylation occurred in this position. The spectrum obtained
74 by ^{19}F NMR analysis showed one signal with a chemical shift of -117.85 ppm and splitting
75 pattern identical to the flurbiprofen, (dd, $J= 11, 8$ Hz), indicating that there were no changes
76 in the proximities of the fluorine atom. The metabolite was dried and further analysed by
77 GC-MS as the per-trimethylsilylated derivative, which was formed by adding $50 \mu\text{l}$ *N*-
78 methyl-*N*-(trimethyl-silyl) trifluoroacetamide (MSTFA) to the solid and heating at 100°C for
79 1 hour. The derivatized compound was diluted in ethyl acetate (1 ml) and an aliquot ($1 \mu\text{l}$)
80 was injected onto a HP-1 column ($12 \text{ m} \times 0.25 \text{ mm} \times 0.33 \mu\text{m}$) and the oven temperature held
81 at 120°C for 2 min then raised to 300°C at $10^\circ\text{C min}^{-1}$. The mass and fragmentation pattern
82 of the metabolite, which had a retention time of 17.50 min, was composed of ions m/z 404
83 (M^+), 389 (M^+-CH_3), 287 (M^+-COOTMS), 268 ($\text{M}^+-\text{COOTMS}, \text{F}$), 253 ($\text{M}^+-\text{COOTMS}, \text{F},$
84 CH_3), and was identical to that described by (20) for 4'-hydroxyflurbiprofen.

85 Metabolic studies of flurbiprofen in human and different animal species reported the
86 presence of several metabolites excreted in urine (15). The major metabolite was identified as
87 4'-hydroxyflurbiprofen and two minor ones as 3',4'-dihydroxyflurbiprofen, 3'-hydroxy-4'-
88 methoxyflurbiprofen. In the present study only one metabolite was detectable by ^{19}F NMR,
89 but since this technique is relatively insensitive additional analyses of the organically
90 extractable metabolites were conducted by HPLC and GC-MS. HPLC analysis of time-
91 course experiments up to 120 hours confirmed that flurbiprofen was completely degraded
92 over three days to one polar metabolite with a retention time of 22.2 min (10-90% acetonitrile

93 over 30 min at 1 ml/min). GC-MS analyses of silylated organically soluble *C. elegans*
94 extracts revealed 4'-hydroxyflurbiprofen and other metabolites that could be tentatively
95 identified as hydroxylated and methoxylated flurbiprofen, based on their mass spectra (Table
96 1).

97 The microbial biotransformation of flurbiprofen was also investigated in selected
98 *Cunninghamella* strains previously shown to transform xenobiotics (4). GC-MS analysis of
99 the organically extractable metabolites, after derivatisation, demonstrated that they all
100 transformed the drug, to varying degrees, yielding the hydroxylated metabolites, and three of
101 the fungi generated hydroxylated methoxyflurbiprofen (Table 2). **Using our methods, no**
102 **other organically soluble fluorometabolites were detected.**

103 Phase II metabolism of flurbiprofen was studied since glucuronide and sulfate
104 flurbiprofen conjugates are reported to be important detoxification metabolites in mammals.
105 In humans, approximately 60-70% of flurbiprofen is excreted as conjugates (1), whereas less
106 than 30% of the flurbiprofen was reportedly conjugated in equine urine (20). Examination of
107 the aqueous extracts from *C. elegans* DSM 1908 by HPLC showed one peak at t_R 17.8 min
108 that was not present in the organic extract analysis, and the ^{19}F NMR spectrum of aqueous
109 phase showed a signal at -119.2 ppm, which had a concentration of 0.1 mg/ml by comparison
110 with an internal standard of sodium fluoride. No fluorometabolites were detected in control
111 experiments. Enzymatic deconjugation was carried out by incubating the aqueous phase with
112 sulfatase (from *Helix pomatia* type H-1), β -glucuronidase (from *Escherichia coli*) and β -
113 glucosidase (from almonds) (Sigma) in phosphate buffer at 37°C for 12 h. The deconjugated
114 reaction products were extracted into ethyl acetate and analysed by GC-MS; 3',4'-
115 dihydroxyflurbiprofen was detected after treatment with sulfatase, but no metabolites were
116 detected in extracts from deconjugation experiments with the other enzymes (Figure 2). The
117 other *Cunninghamella* species were examined for conjugated metabolites, and were only

118 observed in *C. blakesleeana*. The aqueous fraction from a culture of this strain that had been
119 incubated with flurbiprofen was treated with the sequential addition of deconjugation
120 enzymes (added in the order: sulfatase, β -glucuronidase and β -glucosidase) and the reactions
121 monitored by ^{19}F NMR spectroscopy between each addition (Figure 3), demonstrating that
122 the sulfated metabolite was the only phase II compound present. Three resonances were
123 initially observed, and metabolite I disappears after sulfatase treatment, with a concomitant
124 increase in the height of metabolite III. Subsequent treatment with other deconjugative
125 enzymes did not result in any further changes to the spectrum and subsequent HPLC analysis
126 led to the conclusion that metabolites II and III are most likely 4'-hydroxy- and 3',4'-
127 dihydroxy-flubiprofen, respectively.

128 The anti-inflammatory activity of profens, including flurbiprofen, are mainly ascribed
129 to the active (*S*)-enantiomer (14). In human liver microsomes the (*S*)-enantiomer is
130 transformed more rapidly than the (*R*) (19). In order to evaluate differences in the rate of
131 degradation or metabolite formation between chiral and racemic flurbiprofen in fungi,
132 biotransformation experiments were carried out using (*R*)-flurbiprofen. No difference in the
133 formation of phase I and II metabolites was observed; the degradation was complete and
134 comparable with the racemic flurbiprofen (data not shown). (*R*)-flurbiprofen was
135 biotransformed predominantly to 4'-hydroxyflurbiprofen that was found to be identical to
136 that produced by the racemate, based on ^{19}F NMR and GC-MS analysis.

137 Previous studies showed that flurbiprofen has strong antifungal activity (6), so its
138 effect on *C. elegans* DSM 1908 growth was investigated by incubating fungal spore
139 suspension into Sabouraud dextrose liquid medium in 6-well plates (Sarstedt), with different
140 concentrations of drug (0.1-5 mg/ml) added after 0, 6, 24 and 72 hours. Flurbiprofen
141 completely inhibited germination starting at the lowest concentration administered at 0 and 6
142 hours; in the medium there was no presence of mature pellets of mycelium but only the

143 fragments of starting spore suspension. However, when flurbiprofen was added to cultures
144 that were 24-72 h old, the fungal growth was not inhibited, and there was no difference in the
145 biomass collected from culture flasks used in the biotransformation experiments that had
146 been exposed to flurbiprofen and the control cultures to which no drug was added.

147 We have shown for the first time that flurbiprofen is converted by *Cunninghamella*
148 spp. to a variety of phase I and phase II metabolites (Figure 4) present in several mammalian
149 species including man. Among them, 4'-hydroxyflurbiprofen was confirmed to be the major
150 product being converted by both mammalian and microbial systems. This similarity is
151 remarkable considering that only one mammalian cytochrome P450 isoform can detoxify this
152 drug. In fact, previous chemical inhibition studies confirmed that only P450 2C9 was
153 involved in the 4'-hydroxylation of flurbiprofen in humans (18, 19). *C. elegans* DSM 1908
154 in particular would seem to be an appropriate microbial model of phase I metabolism in
155 mammals since all the major metabolites are produced, in addition to new hydroxy- and
156 hydroxy-methoxy isomers. The upscaling of the biotransformation may also have potential
157 as a method of generating the metabolites as analytical standards, in particular 4'-
158 hydroxyflurbiprofen.

159

160 **Acknowledgement**

161 The authors acknowledge financial assistance from the Environmental Protection Agency
162 STRIVE Programme and thank Yannick Ortin for his support with the analysis of NMR
163 spectra.

164

165 **References**

- 166 1. Adams, W. J., B. E. Bothwell, W. M. Bothwell, G. J. Vangiessen, and D. G.
167 Kaiser. 1987. Simultaneous determination of flurbiprofen and its main metabolite in
168 physiological fluids using liquid chromatography with fluorescence detection. Anal.
169 Chem. **59**:1504-1509.

- 170 2. **Amadio, J., and C. D. Murphy.** 2010. Biotransformation of fluorobiphenyl by
171 *Cunninghamella elegans*. Appl. Microbiol. Biotechnol. **86**:345-351.
- 172 3. **Asha, S., and M. Vidyavathi.** 2009. *Cunninghamella* - A microbial model for drug
173 metabolism studies - A review. Biotechnol. Adv. **27**:16-29.
- 174 4. **Azerad, R.** 1999. Microbial Models of Drug Metabolism. Adv. Biochem. Eng.
175 Biotechnol. **63**:169-218.
- 176 5. **Cannell, R. J. P., A. R. Knaggs, M. J. Dawson, G. R. Manchee, P. J. Eddershaw,
177 I. Waterhouse, D. R. Sutherland, G. D. Bowers, and P. J. Sidebottom.** 1995.
178 Microbial biotransformation of the angiotensin II antagonist GR117289 by
179 *Streptomyces rimosus* to identify a mammalian metabolite. Drug Metab. Dispos.
180 **23**:724-729.
- 181 6. **Chowdhury, B., M. Adak, and S. K. Bose.** 2003. Flurbiprofen, a unique non-
182 steroidal anti-inflammatory drug with antimicrobial activity against *Trichophyton*,
183 *Microsporum* and *Epidermophyton* species. Lett. Appl. Microbiol. **37**:158-161.
- 184 7. **Corcoran, O., J. C. Lindon, R. Hall, I. M. Ismail, and J. K. Nicholson.** 2001. The
185 potential of F-19 NMR spectroscopy for rapid screening of cell cultures for models of
186 mammalian drug metabolism. Analyst **126**:2103-2106.
- 187 8. **Jezequel, S. G.** 1998. Microbial models of mammalian metabolism: uses and misuses
188 (clarification of some misconceptions). J. Mol. Catal. B: Enzymatic **5**:371-377.
- 189 9. **Knadler, M. P., and S. D. Hall.** 1989. High performance liquid chromatography of
190 the enantiomers of flurbiprofen and its metabolites in plasma and urine. J. Chromatog.
191 Biomed. Appl. **494**:173-182.
- 192 10. **Moody, J. D., J. P. Freeman, P. P. Fu, and C. E. Cerniglia.** 2002.
193 Biotransformation of mirtazapine by *Cunninghamella elegans*. Drug Metab. Dispos.
194 **30**:1274-1279.
- 195 11. **Moody, J. D., D. L. Zhang, T. M. Heinze, and C. E. Cerniglia.** 2000.
196 Transformation of amoxapine by *Cunninghamella elegans*. Appl. Environ. Microbiol.
197 **66**:3646-3649.
- 198 12. **Murphy, C. D., B. R. Clark, and J. Amadio.** 2009. Metabolism of fluoroorganic
199 compounds in microorganisms: impacts for the environment and the production of
200 fine chemicals. Appl. Microbiol. Biotechnol. **84**:617-629.
- 201 13. **Osorio-Lozada, A., S. Surapaneni, G. L. Skiles, and R. Subramanian.** 2008.
202 Biosynthesis of drug metabolites using microbes in hollow fiber cartridge reactors:
203 Case study of diclofenac metabolism by *Actinoplanes* species. Drug Metab. Dispos.
204 **36**:234-240.
- 205 14. **Paik, M. J., Y. Lee, J. Goto, and K. R. Kim.** 2004. Chiral discrimination of multiple
206 profens as diastereomeric (R)-(+)-1-phenylethylamides by achiral dual-column gas
207 chromatography. J. Chrom. B **803**:257-265.
- 208 15. **Risdall, P. C., S. S. Adams, E. L. Crampton, and B. Marchant.** 1978. Disposition
209 and metabolism of flurbiprofen in several species including man. Xenobiotica **8**:691-
210 703.
- 211 16. **Smith, R. V., and J. P. Rosazza.** 1974. Microbial models of mammalian metabolism
212 - aromatic hydroxylation. Arch. Biochem. Biophys. **161**:551-558.
- 213 17. **Sun, L., H. H. Huang, L. Liu, and D. F. Zhong.** 2004. Transformation of verapamil
214 by *Cunninghamella blakesleeana*. Appl. Environ. Microbiol. **70**:2722-2727.
- 215 18. **Tracy, T. S., C. Marra, S. A. Wrighton, F. J. Gonzalez, and K. R. Korzekwa.**
216 1996. Studies of flurbiprofen 4'-hydroxylation - Additional evidence suggesting the
217 sole involvement of cytochrome P450 2C9. Biochem. Pharmacol. **52**:1305-1309.
- 218 19. **Tracy, T. S., B. W. Rosenbluth, S. A. Wrighton, F. J. Gonzalez, and K. R.
219 Korzekwa.** 1995. Role of cytochrome P450 2C9 and an allelic variant in the 4'-

220 hydroxylation of (R)-flurbiprofen and (S)-flurbiprofen. *Biochem. Pharmacol.*
221 **49**:1269-1275.

222 20. **Tsitsimpikou, C., M. H. E. Spyridaki, I. Georgoulakis, D. Kouretas, M.**
223 **Konstantinidou, and C. G. Georgakopoulos.** 2001. Elimination profiles of
224 flurbiprofen and its metabolites in equine urine for doping analysis. *Talanta* **55**:1173-
225 1180.

226 21. **Williams, A. J., J. Deck, J. P. Freeman, M. P. Chiarelli, M. D. Adjei, T. M.**
227 **Heinze, and J. B. Sutherland.** 2007. Transformation of flumequine by the fungus
228 *Cunninghamella elegans*. *Chemosphere* **67**:240-243.

229
230
231
232
233
234
235

Table 1. GC-MS data for organic extracts of pertrimethylsilylated flurbiprofen and metabolites produced by *C. elegans* DSM 1908.

Compound	t_R	m/z of M^+	m/z of fragment ions
	(min)	(relative intensity)	(relative intensity)
Flurbiprofen	12.85	316 (40)	301(54) 198(23) 180(100) 165(100) 73(100)
4'-OH-flurbiprofen ^{a,b}	16.15	404 (94)	389(43) 287(43) 268(72) 253(28) 73(100)
OH-flurbiprofen	16.64	404 (38)	389(26) 313(88) 285(100) 158(30) 73(60)
OH-flurbiprofen	16.75	404 (25)	389(13) 313(100) 246(17) 73(46)
OH-flurbiprofen	17.34	404 (6)	389(6) 298(40) 179(100) 73(57)
3',4'-DiOH-flurbiprofen ^a	17.50	492 (55)	477(9) 375(16) 267(46) 73(100)
OH-MeO-flurbiprofen	13.63	434 (31)	419(7) 370(32) 314(80) 212(50) 73(100)
OH-MeO-flurbiprofen	14.68	434 (8)	419(3) 337(3) 129(55) 73(100)

^a The mass spectra of these compounds were identical to those reported by (18)

^b Approximately 80% of the total metabolites (by peak area) was 4'-OH-flurbiprofen.

Table 2. Qualitative analysis by GC-MS of biotransformation of flurbiprofen by *Cunninghamella* species.

Compound	<i>C.elegans</i>	<i>C. elegans</i>	<i>C. elegans</i>	<i>C. echinulata</i>	<i>C. blakesleeana</i>
	1908	8217	63299	1905	1906
Flurbiprofen	-	+	+	-	-
4'-OH-flurbiprofen	+	+	+	+	+
3',4'-DiOH-flurbiprofen	+	+	+	+	+
OH-MeO-flurbiprofen	+	-	-	+	+

Figure legends

Fig. 1. Biotransformation of flurbiprofen and formation of its metabolite 4'-hydroxyflurbiprofen by *C. elegans* 1908 analyzed by ^{19}F NMR at (a) 0, (b) 24 and (c) 72 hours.

Fig. 2. Gas chromatograms of metabolites present in *C. elegans* 1908 aqueous extract after treatment (a) without enzyme, (b) with sulfatase, (c) with β - glucuronidase and (d) β - glucosidase.

Fig. 3. ^{19}F NMR analysis of *C. blakesleeana* 1906 aqueous extracts after treatment (a) without enzyme, (b) with sulfatase, (c) with β - glucuronidase and (d) β - glucosidase.

The enzymes were added sequentially to the same extract.

Fig. 4. Principal biotransformation reactions of flurbiprofen in *C. elegans* 1908.

Figure 1




Fig 2

Abundance







Figure 3




Figure 4

